Aspire BioPharma, Inc. (ASBP) — Cash Flow-to-Debt Ratio
Aspire BioPharma, Inc. (ASBP) has a Cash Flow-to-Debt Ratio of -0.94x as of March 2026, meaning its operating cash flow of $-3.04 Million could theoretically repay -1% of its total liabilities ($3.25 Million) in one year. Check ASBP capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aspire BioPharma, Inc. Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for Aspire BioPharma, Inc. across 5 annual periods. Also explore Aspire BioPharma, Inc. asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Aspire BioPharma, Inc. (2021–2025)
Year-by-year debt coverage analysis for Aspire BioPharma, Inc.. For market capitalisation and broader financial context, see ASBP market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.64x | $-4.92 Million | $7.69 Million | ▼ -307.6% |
| 2024 | -0.16x | $-265.19K | $1.69 Million | ▲ +90.3% |
| 2023 | -1.62x | $-653.11K | $403.33K | ▼ -1177.7% |
| 2022 | -0.13x | $-1.41 Million | $11.12 Million | ▼ -14216.2% |
| 2021 | 0.00x | $-260.00 | $293.70K | — |